CARDIOVASCULAR AND SURVIVAL PARADOXES IN DIALYSIS PATIENTS: Kinetic Studies of Atherogenic Lipoproteins in Hemodialysis Patients: Do They Tell Us More about Their Pathology?
暂无分享,去创建一个
[1] F. Kronenberg,et al. In vivo turnover study demonstrates diminished clearance of lipoprotein(a) in hemodialysis patients. , 2007, Kidney international.
[2] F. Kronenberg,et al. Lipoprotein metabolism and lipid management in chronic kidney disease. , 2007, Journal of the American Society of Nephrology : JASN.
[3] A. Tall,et al. The failure of torcetrapib: was it the molecule or the mechanism? , 2006, Arteriosclerosis, thrombosis, and vascular biology.
[4] F. Kronenberg,et al. Epidemiology of dialysis patients and heart failure patients. , 2006, Seminars in nephrology.
[5] F. Kronenberg,et al. Delayed In Vivo Catabolism of Intermediate-Density Lipoprotein and Low-Density Lipoprotein in Hemodialysis Patients as Potential Cause of Premature Atherosclerosis , 2005, Arteriosclerosis, thrombosis, and vascular biology.
[6] W. März,et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. , 2005, The New England journal of medicine.
[7] K. D. Workgroup. K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. , 2005, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[8] F. Kronenberg,et al. Lipoprotein(a)- and low-density lipoprotein-derived cholesterol in nephrotic syndrome: Impact on lipid-lowering therapy? , 2004, Kidney international.
[9] J. Romijn,et al. A broad-based metabolic approach to study VLDL apoB100 metabolism in patients with ESRD and patients treated with peritoneal dialysis. , 2004, Kidney international.
[10] F. Kronenberg,et al. The apolipoprotein(a) size polymorphism is associated with nephrotic syndrome. , 2004, Kidney international.
[11] N. Powe,et al. Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition. , 2004, JAMA.
[12] F. Kronenberg,et al. Apolipoprotein(a) isoform-specific changes of lipoprotein(a) after kidney transplantation , 2003, European Journal of Human Genetics.
[13] J. Jankowski,et al. The Antioxidant Acetylcysteine Reduces Cardiovascular Events in Patients With End-Stage Renal Failure: A Randomized, Controlled Trial , 2003, Circulation.
[14] H. Koyama,et al. Antibody to oxidized low-density lipoprotein and cardiovascular mortality in end-stage renal disease. , 2002, Kidney international.
[15] N. Powe,et al. Small Apolipoprotein(a) Size Predicts Mortality in End-Stage Renal Disease: The CHOICE Study , 2002, Circulation.
[16] Ashutosh Kumar Singh,et al. Handling of low-density lipoprotein by the renal tubule: release of fragments due to incomplete degradation. , 2002, The Journal of laboratory and clinical medicine.
[17] F. Kronenberg,et al. Apolipoprotein A-IV serum concentrations are elevated in patients with mild and moderate renal failure. , 2002, Journal of the American Society of Nephrology : JASN.
[18] T. Demant,et al. The metabolism of lipoprotein(a) and other apolipoprotein B-containing lipoproteins: a kinetic study in humans. , 2001, Atherosclerosis.
[19] P. Lucidi,et al. Increased albumin and fibrinogen synthesis in hemodialysis patients with normal nutritional status. , 2001, Journal of the American Society of Nephrology : JASN.
[20] M. Boaz,et al. Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial , 2000, The Lancet.
[21] JensPietzsch,et al. Oxidation of Apolipoprotein B-100 in Circulating LDL Is Related to LDL Residence Time , 2000 .
[22] Jens Pietzsch,et al. Oxidation of Apolipoprotein B-100 in Circulating LDL Is Related to LDL Residence Time: In Vivo Insights From Stable-Isotope Studies , 2000, Arteriosclerosis, thrombosis, and vascular biology.
[23] J. Danesh,et al. Lipoprotein(a) and Coronary Heart Disease: Meta-Analysis of Prospective Studies , 2000, Circulation.
[24] F. Kronenberg,et al. Lipoprotein(a) serum concentrations and apolipoprotein(a) phenotypes in mild and moderate renal failure. , 2000, Journal of the American Society of Nephrology : JASN.
[25] Y. Kawaguchi,et al. Role of hepatic lipase in intermediate-density lipoprotein and small, dense low-density lipoprotein formation in hemodialysis patients. , 1999, Kidney international. Supplement.
[26] G. Kaysen,et al. New insights into lipid metabolism in the nephrotic syndrome. , 1999, Kidney international. Supplement.
[27] F. Kronenberg,et al. Lipoprotein(a) plasma concentrations after renal transplantation: a prospective evaluation after 4 years of follow-up. , 1999, Atherosclerosis.
[28] H. Milionis,et al. Apolipoprotein(a) phenotypes and lipoprotein(a) concentrations in patients with renal failure. , 1999, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[29] F. Kronenberg,et al. The low molecular weight apo(a) phenotype is an independent predictor for coronary artery disease in hemodialysis patients: a prospective follow-up. , 1999, Journal of the American Society of Nephrology : JASN.
[30] C. Wanner,et al. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. , 1999, Kidney international.
[31] R. Foley,et al. Clinical epidemiology of cardiovascular disease in chronic renal disease. , 1998, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[32] J. Haddow,et al. Lipoprotein(a) as a risk factor for ischemic heart disease: metaanalysis of prospective studies. , 1998, Clinical chemistry.
[33] T. Rabelink,et al. Evidence for increased synthesis of lipoprotein(a) in the nephrotic syndrome. , 1998, Journal of the American Society of Nephrology : JASN.
[34] T. Shoji,et al. Intermediate-density lipoprotein as an independent risk factor for aortic atherosclerosis in hemodialysis patients. , 1998, Journal of the American Society of Nephrology : JASN.
[35] P. Stenvinkel,et al. Apo(a)-isoform size, nutritional status and inflammatory markers in chronic renal failure. , 1998, Kidney international.
[36] C. Wanner,et al. Receptor-mediated lipoprotein uptake by human glomerular cells: comparison with skin fibroblasts and HepG2 cells. , 1997, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[37] G. Kaysen. Albumin Turnover in Renal Disease , 1997, Mineral and Electrolyte Metabolism.
[38] F. Kronenberg,et al. Renovascular arteriovenous differences in Lp[a] plasma concentrations suggest removal of Lp[a] from the renal circulation. , 1997, Journal of lipid research.
[39] K. Kostner,et al. Urinary excretion of apo(a) fragments. Role in apo(a) catabolism. , 1996, Arteriosclerosis, thrombosis, and vascular biology.
[40] D. Rader,et al. ApoA-II kinetics in humans using endogenous labeling with stable isotopes: slower turnover of apoA-II compared with the exogenous radiotracer method. , 1996, Journal of lipid research.
[41] H. Hobbs,et al. Apolipoprotein(a) kringle 4-containing fragments in human urine. Relationship to plasma levels of lipoprotein(a). , 1996, The Journal of clinical investigation.
[42] F. Kronenberg,et al. Multicenter study of lipoprotein(a) and apolipoprotein(a) phenotypes in patients with end-stage renal disease treated by hemodialysis or continuous ambulatory peritoneal dialysis. , 1995, Journal of the American Society of Nephrology : JASN.
[43] K. Huttunen,et al. Decreased clearance of low-density lipoprotein in uremic patients under dialysis treatment. , 1995, Kidney international.
[44] F. Kronenberg,et al. Apolipoprotein(a) phenotype-associated decrease in lipoprotein(a) plasma concentrations after renal transplantation. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.
[45] F. Kronenberg,et al. Apolipoprotein(a) phenotypes predict the risk for carotid atherosclerosis in patients with end-stage renal disease. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.
[46] K. Huttunen,et al. Decreased clearance of low-density lipoprotein in patients with chronic renal failure. , 1994, Kidney international.
[47] D. Rader,et al. Delayed catabolism of high density lipoprotein apolipoproteins A-I and A-II in human cholesteryl ester transfer protein deficiency. , 1993, The Journal of clinical investigation.
[48] D. Rader,et al. Elevated Plasma Lipoprotein(a) in Patients with the Nephrotic Syndrome , 1993, Annals of Internal Medicine.
[49] F. Kronenberg,et al. Elevated plasma concentrations of lipoprotein(a) in patients with end-stage renal disease are not related to the size polymorphism of apolipoprotein(a). , 1993, The Journal of clinical investigation.
[50] S. Grundy,et al. Influence of lovastatin therapy on metabolism of low density lipoproteins in mixed hyperlipidaemia , 1991, Journal of internal medicine.
[51] A. del Río. [Lipoprotein (a)]. , 1991, Medicina clinica.
[52] P. Attman,et al. Lipid and apolipoprotein profiles of uremic dyslipoproteinemia--relation to renal function and dialysis. , 1991, Nephron.
[53] B. Gordon,et al. Plasmin catalyzes binding of lipoprotein (a) to immobilized fibrinogen and fibrin. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[54] Z. Varghese,et al. Apolipoprotein B turnover in dialysis patients: its relationship to pathogenesis of hyperlipidemia. , 1989, Clinical nephrology.